Free Trial

argenx (ARGX) Stock Forecast & Price Target

argenx logo
$622.31 +7.20 (+1.17%)
As of 10:05 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

argenx - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
3
Buy
20

Based on 23 Wall Street analysts who have issued ratings for argenx in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 23 analysts, 3 have given a hold rating, 19 have given a buy rating, and 1 has given a strong buy rating for ARGX.

Consensus Price Target

$699.28
12.37% Upside
According to the 23 analysts' twelve-month price targets for argenx, the average price target is $699.28. The highest price target for ARGX is $1,100.00, while the lowest price target for ARGX is $500.00. The average price target represents a forecasted upside of 12.37% from the current price of $622.31.
Get the Latest News and Ratings for ARGX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for argenx and its competitors.

Sign Up

ARGX Analyst Ratings Over Time

TypeCurrent Forecast
5/7/24 to 5/7/25
1 Month Ago
4/7/24 to 4/7/25
3 Months Ago
2/7/24 to 2/6/25
1 Year Ago
5/8/23 to 5/7/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
19 Buy rating(s)
19 Buy rating(s)
18 Buy rating(s)
14 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
2 Hold rating(s)
5 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$699.28$687.00$658.39$528.16
Forecasted Upside12.37% Upside24.91% Upside0.06% Upside32.43% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

ARGX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ARGX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

argenx Stock vs. The Competition

TypeargenxMedical CompaniesS&P 500
Consensus Rating Score
2.91
2.81
2.54
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside13.68% Upside3,854.29% Upside18.94% Upside
News Sentiment Rating
Positive News

See Recent ARGX News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/17/2025Citigroup
2 of 5 stars
Samantha Semenkow
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$681.00 ➝ $796.00+33.84%
4/11/2025Wedbush
3 of 5 stars
David Nierengarten
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$715.00 ➝ $715.00+23.83%
4/8/2025HC Wainwright
1 of 5 stars
Douglas Tsao
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$720.00 ➝ $720.00+31.16%
3/17/2025Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Smith
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform
3/12/2025Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeSell ➝ Hold
3/10/2025Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Yatin Suneja
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$775.00 ➝ $1,100.00+91.18%
3/4/2025Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Joel Beatty
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetNeutral ➝ Neutral$650.00 ➝ $680.00+7.68%
2/28/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Derek Archila
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$723.00 ➝ $741.00+19.70%
2/28/2025Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Leland Gershell
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$675.00 ➝ $704.00+13.72%
2/28/2025William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Minter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
1/14/2025Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Joon Lee
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$660.00 ➝ $700.00+3.93%
1/14/2025JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Jason Butler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetMarket Outperform ➝ Market Outperform$606.00 ➝ $696.00+3.82%
1/7/2025Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$620.00 ➝ $725.00+12.34%
11/21/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$675.00 ➝ $706.00+19.29%
11/12/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Chen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradePeer Perform ➝ Outperform$697.00+18.35%
11/5/2024Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
G. Farmer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSector Perform ➝ Sector Outperform$439.00 ➝ $715.00+21.46%
11/4/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$640.00 ➝ $670.00+12.61%
11/1/2024Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Beatty
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
10/10/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Brill
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingStrong-Buy$605.00+16.23%
8/6/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Pitman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight
6/24/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$535.00 ➝ $607.00+40.57%
6/24/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$485.00 ➝ $500.00+14.82%
5/28/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$515.00 ➝ $510.00+39.29%
12/12/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$612.00 ➝ $641.00+41.35%
10/2/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$605.00 ➝ $628.00+29.56%
7/24/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$480.00 ➝ $570.00+3.93%
6/15/2023Societe Generale
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageSell

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 10:05 AM ET.


Should I Buy argenx Stock? ARGX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, May 5, 2025. Please send any questions or comments about these argenx pros and cons to contact@marketbeat.com.

argenx
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in argenx SE:

  • The current stock price is around $656.65, reflecting a strong performance in the market.
  • Recent earnings results showed an EPS of $1.58, significantly exceeding analyst expectations, indicating strong financial health.
  • The company has received a majority of buy ratings from analysts, suggesting positive market sentiment and potential for growth.
  • With a market cap of approximately $40.10 billion, argenx SE is positioned as a significant player in the biotechnology sector, which can attract more institutional investments.
  • Recent revenue of $761.22 million surpassed estimates, showcasing the company's ability to generate strong sales and potentially leading to future profitability.

argenx
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in argenx SE for these reasons:

  • The company has a negative price-to-earnings ratio, indicating that it is currently not profitable, which can be a red flag for some investors.
  • Despite strong revenue, argenx SE has a negative net margin, suggesting that it is not yet effectively converting sales into profit.
  • Market volatility can impact stock performance, and the biotechnology sector is often subject to rapid changes in investor sentiment.
  • With a beta of 0.57, the stock is less volatile than the market, which may limit potential high returns for aggressive investors.
  • Institutional ownership is significant, which can lead to volatility if large investors decide to sell their stakes.

ARGX Forecast - Frequently Asked Questions

According to the research reports of 23 Wall Street equities research analysts, the average twelve-month stock price forecast for argenx is $699.28, with a high forecast of $1,100.00 and a low forecast of $500.00.

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for argenx in the last year. There are currently 3 hold ratings, 19 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ARGX shares.

According to analysts, argenx's stock has a predicted upside of 12.37% based on their 12-month stock forecasts.

Over the previous 90 days, argenx's stock had 2 upgrades by analysts.

Analysts like argenx more than other "medical" companies. The consensus rating score for argenx is 2.91 while the average consensus rating score for "medical" companies is 2.82. Learn more on how ARGX compares to other companies.


This page (NASDAQ:ARGX) was last updated on 5/7/2025 by MarketBeat.com Staff
From Our Partners